Tags

Type your tag names separated by a space and hit enter

Mesenchymal stem cells and their potential as cardiac therapeutics.
Circ Res. 2004 Jul 09; 95(1):9-20.CircR

Abstract

Mesenchymal stem cells (MSCs) represent a stem cell population present in adult tissues that can be isolated, expanded in culture, and characterized in vitro and in vivo. MSCs differentiate readily into chondrocytes, adipocytes, osteocytes, and they can support hematopoietic stem cells or embryonic stem cells in culture. Evidence suggests MSCs can also express phenotypic characteristics of endothelial, neural, smooth muscle, skeletal myoblasts, and cardiac myocyte cells. When introduced into the infarcted heart, MSCs prevent deleterious remodeling and improve recovery, although further understanding of MSC differentiation in the cardiac scar tissue is still needed. MSCs have been injected directly into the infarct, or they have been administered intravenously and seen to home to the site of injury. Examination of the interaction of allogeneic MSCs with cells of the immune system indicates little rejection by T cells. Persistence of allogeneic MSCs in vivo suggests their potential "off the shelf" therapeutic use for multiple recipients. Clinical use of cultured human MSCs (hMSCs) has begun for cancer patients, and recipients have received autologous or allogeneic MSCs. Research continues to support the desirable traits of MSCs for development of cellular therapeutics for many tissues, including the cardiovascular system. In summary, hMSCs isolated from adult bone marrow provide an excellent model for development of stem cell therapeutics, and their potential use in the cardiovascular system is currently under investigation in the laboratory and clinical settings.

Authors+Show Affiliations

Osiris Therapeutics, Inc., 2001 Aliceanna St, Baltimore, MD 21231, USA. mpittenger@osiristx.comNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15242981

Citation

Pittenger, Mark F., and Bradley J. Martin. "Mesenchymal Stem Cells and Their Potential as Cardiac Therapeutics." Circulation Research, vol. 95, no. 1, 2004, pp. 9-20.
Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004;95(1):9-20.
Pittenger, M. F., & Martin, B. J. (2004). Mesenchymal stem cells and their potential as cardiac therapeutics. Circulation Research, 95(1), 9-20.
Pittenger MF, Martin BJ. Mesenchymal Stem Cells and Their Potential as Cardiac Therapeutics. Circ Res. 2004 Jul 9;95(1):9-20. PubMed PMID: 15242981.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mesenchymal stem cells and their potential as cardiac therapeutics. AU - Pittenger,Mark F, AU - Martin,Bradley J, PY - 2004/7/10/pubmed PY - 2004/12/16/medline PY - 2004/7/10/entrez SP - 9 EP - 20 JF - Circulation research JO - Circ. Res. VL - 95 IS - 1 N2 - Mesenchymal stem cells (MSCs) represent a stem cell population present in adult tissues that can be isolated, expanded in culture, and characterized in vitro and in vivo. MSCs differentiate readily into chondrocytes, adipocytes, osteocytes, and they can support hematopoietic stem cells or embryonic stem cells in culture. Evidence suggests MSCs can also express phenotypic characteristics of endothelial, neural, smooth muscle, skeletal myoblasts, and cardiac myocyte cells. When introduced into the infarcted heart, MSCs prevent deleterious remodeling and improve recovery, although further understanding of MSC differentiation in the cardiac scar tissue is still needed. MSCs have been injected directly into the infarct, or they have been administered intravenously and seen to home to the site of injury. Examination of the interaction of allogeneic MSCs with cells of the immune system indicates little rejection by T cells. Persistence of allogeneic MSCs in vivo suggests their potential "off the shelf" therapeutic use for multiple recipients. Clinical use of cultured human MSCs (hMSCs) has begun for cancer patients, and recipients have received autologous or allogeneic MSCs. Research continues to support the desirable traits of MSCs for development of cellular therapeutics for many tissues, including the cardiovascular system. In summary, hMSCs isolated from adult bone marrow provide an excellent model for development of stem cell therapeutics, and their potential use in the cardiovascular system is currently under investigation in the laboratory and clinical settings. SN - 1524-4571 UR - https://www.unboundmedicine.com/medline/citation/15242981/Mesenchymal_stem_cells_and_their_potential_as_cardiac_therapeutics_ L2 - http://www.ahajournals.org/doi/full/10.1161/01.RES.0000135902.99383.6f?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -